Document is current
Any future updates will be listed below
-
Authors
Jin, Zhili
Wu, Jingxuan
Huang, Tao
Zhao, Kexin
Zhang, Meijuan
Liu, Jun
Song, Jian
Yin, Hang
Wu, Xiaofang
Liu, Jian
Zhu, Tao
Huang, Haitao
Li, Jin
Wang, Haomeng
Gou, Jinbo
Dong, Ruihua
-
Funding
Funding for this research was provided by:
the Natural Science Foundation of Beijing Municipal (7254325)
the Capital’s Funds for Health Improvement and Research (2022-2Z-20216)
the National Key Research and Development Program of China (2024YFF1207000)
- License Information
-
More Information
Article History
Received: 10 August 2025
Accepted: 29 October 2025
First Online: 20 November 2025
Declarations
:
: All versions of the clinical trial protocol and related documents underwent review and approval by the Institutional Review Board of Beijing Friendship Hospital, Capital Medical University (2022-P1-drug 030 − 03). The study was performed in accordance with the ethical standards as laid down in the Declaration of Helsinki. Informed consent was obtained from all subjects involved in the study.
: Not applicable.
: Authors Jian Liu, Tao Zhu, Haitao Huang, Jin Li, Haomeng Wang, Jinbo Gou were employed by the CanSino (Shanghai) Biotechnologies Co., Ltd., CanSino (Shanghai) Biological Research Co., Ltd. and CanSino Biologics Inc (Tianjin). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from CanSino (Shanghai) Biotechnologies Co., Ltd. and CanSino Biologics Inc (Tianjin). The funder had the following involvement in the study: study design and the decision to submit it for publication.
